Phospho-CFL1 (Tyr139) Antibody

What is the Phospho-CFL1 (Tyr139) Antibody and what biological function does it detect?

The Phospho-CFL1 (Tyr139) antibody is a polyclonal antibody specifically designed to recognize the phosphorylated form of cofilin-1 (CFL1) at tyrosine 139. CFL1 is an actin-binding protein that controls actin polymerization and depolymerization in a pH-sensitive manner, binding both G- and F-actin in a 1:1 ratio. This protein serves as a major component of intranuclear and cytoplasmic actin rods . The antibody specifically targets the phosphorylated tyrosine within the peptide sequence N-C-Y(p)-E-E derived from human cofilin . Phosphorylation at this site represents a post-translational modification that may regulate CFL1's function in cytoskeletal dynamics and cellular signaling pathways.

The antibody enables researchers to specifically detect this phosphorylation state without cross-reactivity to the non-phosphorylated form, making it valuable for studying signal transduction pathways involving CFL1 regulation. By using this antibody, researchers can distinguish between active and inactive states of cofilin, providing insights into mechanisms controlling actin cytoskeleton remodeling.

What are the technical specifications of commercially available Phospho-CFL1 (Tyr139) antibodies?

Commercial Phospho-CFL1 (Tyr139) antibodies typically share the following specifications:

These antibodies are purified through affinity chromatography using epitope-specific phosphopeptides, with non-phospho specific antibodies removed through chromatography using non-phosphopeptide . This dual purification approach ensures high specificity for the phosphorylated epitope, which is critical for phosphorylation-dependent studies.

How does the specificity of Phospho-CFL1 (Tyr139) antibody compare to pan-phosphotyrosine antibodies?

Phospho-CFL1 (Tyr139) antibody represents a phosphorylation state-specific antibody (PSSA) that provides significant advantages over pan-phosphotyrosine antibodies in certain research contexts. While pan-reactive antibodies against modified amino acids (such as anti-phosphotyrosine) can detect phosphorylation events broadly, they require isolation of the specific protein prior to analysis and cannot identify the specific residue that has been modified when multiple amino acids might be phosphorylated .

In contrast, the Phospho-CFL1 (Tyr139) antibody recognizes the post-translational modification within a specific amino acid sequence context. This specificity allows researchers to directly study the timeline and dynamics of phosphorylation at this particular residue during signal cascades without prior protein isolation steps . The phospho-specific design enables examination of site-specific modifications that may have distinct functional consequences compared to phosphorylation at other sites on the same protein.

For researchers investigating cofilin regulation specifically, this targeted approach provides more precise data on the Tyr139 phosphorylation state than would be possible with pan-phosphotyrosine antibodies, enabling detailed mechanistic studies of cofilin's role in actin dynamics.

What methodological approaches improve signal-to-noise ratio when using Phospho-CFL1 (Tyr139) antibody in immunohistochemistry?

Optimizing signal-to-noise ratio when using Phospho-CFL1 (Tyr139) antibody for immunohistochemistry (IHC) requires several methodological considerations:

First, thorough blocking is essential. For phospho-specific antibodies, dual blocking with both protein blockers (3-5% BSA) and phosphatase inhibitors is critical to prevent dephosphorylation during sample processing. Second, antibody dilution optimization is necessary—while the recommended range is 1:50-1:100 , researchers should perform a dilution series to determine optimal concentration for their specific tissue and fixation method.

Signal amplification systems such as tyramide signal amplification (TSA) can significantly improve detection of low-abundance phospho-epitopes. When multiple antibodies are used, strategic ordering of primary antibodies is important—applying the phospho-specific antibody first often yields better results when dual staining is performed.

Finally, appropriate negative controls should include both a non-phosphorylated peptide competition assay and phosphatase-treated tissue sections to verify phospho-specificity of the observed signal. These methodological refinements collectively enhance the reliability and specificity of phospho-CFL1 detection in tissue samples.

How can researchers validate the specificity of Phospho-CFL1 (Tyr139) antibody in their experimental system?

Validation of Phospho-CFL1 (Tyr139) antibody specificity requires a multi-faceted approach:

One critical validation method involves phosphatase treatment, where treating duplicate samples with lambda phosphatase prior to immunoblotting should eliminate the signal if the antibody is truly phospho-specific. Additionally, peptide competition assays using both phosphorylated and non-phosphorylated peptides around the Tyr139 site can confirm specificity—the phospho-peptide should block antibody binding while the non-phosphorylated version should not.

Genetic approaches provide another validation strategy. Using CFL1 knockdown/knockout systems or cells expressing phospho-deficient mutants (Y139F) should show reduced or absent antibody reactivity. Conversely, expressing phosphomimetic mutants or stimulating cells with phosphorylation-inducing treatments should enhance the signal.

Orthogonal methods should also be employed. Researchers can use mass spectrometry to independently confirm phosphorylation at Tyr139 in their specific experimental conditions. Furthermore, using multiple antibodies targeting different epitopes of phospho-CFL1 can provide confirmation of results across different detection reagents.

Application-specific validation is equally important. For ELISA applications, comparing phosphopeptide versus non-phosphopeptide standard curves helps determine specificity and sensitivity thresholds . For IHC applications, researchers should optimize antigen retrieval methods and validate staining patterns across different tissue types, comparing results with known expression patterns of CFL1 .

What are the current challenges in developing highly specific phospho-antibodies like Phospho-CFL1 (Tyr139)?

Development of highly specific phospho-antibodies such as the Phospho-CFL1 (Tyr139) antibody faces several significant challenges that researchers should be aware of:

A major challenge is the relatively modest binding affinities typically achieved. Phospho-specific antibodies often have binding affinities in the range of 40–5,000 nM, which, while comparable to previously reported phospho-specific antibodies, may present limitations for detecting low-abundance phosphorylated targets . This relatively low affinity stems partly from the subtle nature of the phosphorylation modification and the conformational changes it induces.

The peptide design phase presents another critical challenge. Creating immunogens that properly present the phospho-epitope while maintaining accessibility and specificity requires careful consideration of peptide length, flanking sequences, and conjugation chemistry. The immunization approach must also be optimized to elicit antibodies with the desired specificity profile.

Cross-reactivity with structurally similar phospho-epitopes remains an ongoing concern. Phosphorylation sites often exist within similar sequence contexts across different proteins, making absolute specificity difficult to achieve. Extensive negative selection steps during antibody purification are necessary to remove antibodies that might cross-react with similar phospho-epitopes or with the non-phosphorylated form of the target protein .

Recent advances in antibody engineering have addressed some of these challenges. Key improvements include eliminating residues with unsatisfied polar groups in the complementarity-determining regions (CDRs) and introducing or removing charged residues at peripheral sites within the CDRs . These modifications can enhance binding affinity by optimizing the energetics of antibody-antigen interactions.

How should researchers optimize Western blot protocols for Phospho-CFL1 (Tyr139) antibody to ensure phospho-epitope preservation?

Optimizing Western blot protocols for Phospho-CFL1 (Tyr139) antibody requires careful attention to preserving the phosphorylation state throughout sample preparation and detection:

Cell or tissue lysis should be performed using ice-cold RIPA or NP-40 buffer supplemented with both protease inhibitors and phosphatase inhibitors (sodium fluoride, sodium orthovanadate, and sodium pyrophosphate). The pH of lysis buffers should be carefully maintained between 7.2-7.4 to preserve phospho-epitope integrity. Rapid processing is essential—samples should be kept on ice and processed immediately after lysis to minimize dephosphorylation.

For gel electrophoresis, using freshly prepared SDS-PAGE gels is recommended, as aged gels may contain active phosphatases. Transferring at lower voltage for longer durations (e.g., 30V overnight at 4°C) often improves retention of phosphoproteins compared to rapid high-voltage transfers. When blocking membranes, phosphate-buffered saline (PBS) should be replaced with Tris-buffered saline (TBS) for all wash steps, as phosphate buffers can interfere with phospho-detection.

Primary antibody incubation should follow the manufacturer's recommended dilution (likely requiring optimization around the 1:100 to 1:1000 range based on typical phospho-antibodies). Extended incubation periods (overnight at 4°C) often yield better results than shorter incubations. Incorporating 5% BSA rather than milk in antibody dilution buffers is critical, as milk contains phosphatases that can dephosphorylate the epitope.

Signal detection systems with enhanced sensitivity, such as chemiluminescent substrates with extended signal duration, allow for optimal exposure time determination. Parallel blots with total CFL1 antibody provide essential normalization controls to distinguish between changes in phosphorylation versus changes in total protein levels.

What are the recommended approaches for quantifying Phospho-CFL1 (Tyr139) levels in different experimental systems?

Quantification of Phospho-CFL1 (Tyr139) levels requires tailored approaches depending on the experimental system:

For cell culture systems, quantitative Western blotting represents the gold standard approach. When implementing this method, researchers should always normalize phospho-CFL1 signal to total CFL1 levels to account for variations in protein expression. Digital imaging systems with wide dynamic range are preferred over film for accurate quantification. Standard curves using recombinant phosphorylated and non-phosphorylated CFL1 can provide absolute quantification capabilities.

ELISA-based quantification offers higher throughput but requires careful validation. Commercial ELISA kits for Phospho-CFL1 (Tyr139) may not be widely available, so researchers might need to develop sandwich ELISA systems using capture antibodies against total CFL1 and detection antibodies specific for the Tyr139 phosphorylated form . Standard curves should be generated using synthetic phosphopeptides.

For tissue samples, quantitative immunohistochemistry can be employed using digital image analysis. This approach requires standardized staining protocols, calibration slides with known quantities of target proteins, and sophisticated image analysis software capable of distinguishing nuclear versus cytoplasmic staining patterns.

Phosphoproteomic mass spectrometry provides an orthogonal approach for absolute quantification. Selected reaction monitoring (SRM) or parallel reaction monitoring (PRM) mass spectrometry using isotopically labeled synthetic phosphopeptide standards enables precise quantification of phosphorylation stoichiometry at specific sites. This method is particularly valuable for complex samples or when antibody specificity is uncertain.

For all quantification methods, appropriate statistical analysis is crucial. Researchers should report both the fold-change in phosphorylation and the phosphorylation stoichiometry (percentage of total protein that is phosphorylated) when possible, as these provide complementary insights into signaling dynamics.

How can researchers effectively use Phospho-CFL1 (Tyr139) antibody in studying actin dynamics in neuronal systems?

Studying actin dynamics in neuronal systems using Phospho-CFL1 (Tyr139) antibody requires specialized approaches tailored to neuronal biology:

For primary neuronal cultures, immunocytochemistry with Phospho-CFL1 (Tyr139) antibody can visualize the subcellular distribution of phosphorylated cofilin. When implementing this technique, researchers should co-stain with phalloidin (F-actin marker) and total cofilin antibodies to correlate phosphorylation status with actin filament organization. Time-course experiments following neuronal stimulation (e.g., BDNF treatment, glutamate receptor activation) can reveal the temporal dynamics of cofilin phosphorylation during cytoskeletal remodeling.

Live imaging approaches can provide dynamic information. While direct live imaging with antibodies isn't possible, researchers can use fixed-timepoint antibody staining after live imaging of fluorescently-tagged actin to correlate actin dynamics with subsequent cofilin phosphorylation states. For neuronal tissues, layer-specific or region-specific analysis of phospho-CFL1 in brain sections can reveal differential regulation across neuronal populations.

Biochemical fractionation approaches are particularly valuable in neuronal systems. Researchers can separate cytoskeletal and cytosolic fractions before Western blotting with Phospho-CFL1 (Tyr139) antibody to determine the distribution of phosphorylated cofilin between soluble and actin-bound pools . Synaptosomal preparations can further isolate phospho-cofilin specifically at synaptic compartments, where actin remodeling is critical for synaptic plasticity.

In neurodevelopmental studies, examining phospho-CFL1 during stages of axon formation, dendrite arborization, and synapse formation can reveal regulatory mechanisms of cytoskeletal dynamics. For neurological disease models, comparing phospho-CFL1 levels between control and disease conditions may identify cytoskeletal regulatory abnormalities relevant to pathogenesis, particularly in disorders affecting neuronal structure or migration.

What are common pitfalls when using Phospho-CFL1 (Tyr139) antibody and how can researchers avoid them?

When working with Phospho-CFL1 (Tyr139) antibody, researchers should be aware of several common pitfalls:

A frequent issue is phospho-epitope dephosphorylation during sample handling. To prevent this, all buffers should contain phosphatase inhibitor cocktails including sodium fluoride (50mM), sodium orthovanadate (2mM), and β-glycerophosphate (10mM). Sample processing time should be minimized, and all steps performed at 4°C whenever possible. Additionally, phosphatase inhibitors should be refreshed in buffers that have been stored for extended periods.

Cross-reactivity with structurally similar phospho-epitopes presents another challenge. Researchers should verify antibody specificity through peptide competition assays using both the phosphorylated target sequence and structurally similar phospho-peptides from other proteins. When possible, validation in knockout/knockdown systems provides definitive evidence of specificity.

Variable phosphorylation levels due to culture conditions can produce inconsistent results. Standardizing cell density, serum conditions, and time between media changes helps minimize variation. For in vivo samples, consistent timing of tissue collection relative to circadian rhythms and feeding patterns is critical, as these factors can influence signaling pathway activation.

Batch-to-batch variation in antibody performance is a common issue with polyclonal antibodies. Researchers should validate each new antibody lot against previous lots using positive control samples with confirmed phospho-CFL1 (Tyr139) expression. Purchasing larger antibody quantities from single lots for long-term projects helps maintain consistency.

Inappropriate storage conditions leading to antibody degradation can compromise results. Antibodies should be stored according to manufacturer recommendations (typically -20°C or -80°C) , with minimal freeze-thaw cycles. Aliquoting antibodies upon receipt prevents repeated freeze-thaw cycles that degrade antibody quality over time.

How can researchers integrate Phospho-CFL1 (Tyr139) antibody data with other methods to comprehensively study actin cytoskeleton regulation?

Effective integration of Phospho-CFL1 (Tyr139) antibody data with complementary techniques provides a comprehensive view of actin cytoskeleton regulation:

Correlative microscopy approaches can directly link phosphorylation status to cytoskeletal structure. Researchers can combine immunofluorescence using Phospho-CFL1 (Tyr139) antibody with super-resolution microscopy of actin filaments to establish spatial relationships between phospho-cofilin localization and actin network architecture at nanoscale resolution. Additionally, electron microscopy following immunogold labeling can precisely localize phospho-cofilin relative to specific actin structures.

Functional assays provide important context for phosphorylation data. Actin polymerization assays using pyrene-labeled actin can determine how phospho-cofilin affects polymerization kinetics. Live-cell imaging of actin dynamics using fluorescent actin probes (LifeAct, SiR-actin) can be correlated with fixed-cell immunostaining of phospho-cofilin to link dynamic events with phosphorylation states.

Biochemical approaches add mechanistic insights. Immunoprecipitation with Phospho-CFL1 (Tyr139) antibody followed by mass spectrometry can identify binding partners specific to the phosphorylated form. In vitro phosphorylation assays using purified kinases can establish direct enzymatic relationships. F-actin/G-actin fractionation assays combined with phospho-cofilin detection demonstrate how phosphorylation alters the balance between filamentous and globular actin pools.

Genetic manipulation provides causal evidence. CRISPR-engineered phospho-mutants (Y139F, Y139E) can be compared with wild-type CFL1 to establish the functional significance of this specific phosphorylation site. Conditionally activatable kinases or phosphatases targeting CFL1 enable temporal control of phosphorylation to determine acute effects on cytoskeletal dynamics.

Integration of these approaches with computational modeling of actin dynamics incorporating phospho-regulation parameters can generate testable predictions about how Tyr139 phosphorylation influences cellular processes dependent on actin remodeling.

How do recent advances in antibody engineering impact the development and application of phospho-specific antibodies like Phospho-CFL1 (Tyr139)?

Recent advances in antibody engineering have significantly impacted phospho-specific antibody development, with important implications for reagents like Phospho-CFL1 (Tyr139) antibody:

Phage display technology has revolutionized phospho-specific antibody production. This approach enables selection of antibodies with selective and improved affinity for specific phosphorylation states by randomizing complementarity-determining region (CDR) residues. This technique has generated phospho-specific antibodies for a wide range of targets with modified serine, threonine, and tyrosine residues . For phospho-CFL1 antibodies, this approach allows fine-tuning of specificity for the exact phosphorylation context around Tyr139.

Strategic CDR mutations have emerged as a key optimization strategy. Two particularly important types of mutations have been identified: first, eliminating residues with unsatisfied polar groups (such as asparagine or threonine side chains) where desolvation isn't compensated by favorable interactions in the bound state. Replacing these with small hydrophobic residues increases binding affinity . Second, introducing or removing charged residues at peripheral sites within the CDRs can increase on-rate and thereby affinity of phospho-specific antibodies .

Combined computational approaches significantly enhance antibody stability and specificity. Integration of knowledge-based approaches, statistical methods like covariation analysis, and structure-based computational modeling can identify positions critical for stability. One study demonstrated that this combined approach identified 18 stabilizing mutations at 10 different positions in a single-chain variable fragment, dramatically increasing thermal stability (melting temperature increased from 51°C to 82°C) .

These engineering advances directly benefit phospho-specific antibody applications by producing reagents with greater specificity, stability, and binding affinity. For researchers using Phospho-CFL1 (Tyr139) antibody, next-generation reagents developed using these techniques may offer superior performance characteristics, including lower background, enhanced sensitivity for detecting low-abundance phosphorylated species, and improved stability under varying experimental conditions.

What are the future directions for research utilizing Phospho-CFL1 (Tyr139) antibody?

Future research utilizing Phospho-CFL1 (Tyr139) antibody will likely expand in several promising directions as cytoskeletal regulation continues to emerge as a critical component in diverse biological processes.

In neuroscience, the antibody will play an increasingly important role in elucidating how cofilin phosphorylation at Tyr139 contributes to synaptic plasticity, neurodevelopmental processes, and neurodegenerative pathologies. As signaling pathways connecting neural activity to cytoskeletal remodeling become better understood, phospho-CFL1 (Tyr139) may emerge as a key regulatory node linking extracellular signals to structural changes at synapses.

Cancer research represents another frontier where this antibody will prove valuable. Investigating the role of tyrosine-phosphorylated cofilin in tumor cell invasion and metastasis may reveal new therapeutic targets. High-throughput screening of compounds that modulate CFL1 Tyr139 phosphorylation could identify potential anti-metastatic agents. Correlation studies examining phospho-CFL1 (Tyr139) levels across tumor types and stages might establish its utility as a prognostic biomarker.

At the technological level, integration with emerging single-cell analysis methods will enable researchers to examine cell-to-cell variation in cofilin phosphorylation status. Combining phospho-CFL1 (Tyr139) detection with spatial transcriptomics or with multiplexed protein profiling techniques will provide unprecedented insights into how cytoskeletal regulation varies across tissues and microenvironments.

Structural biology approaches focusing on how Tyr139 phosphorylation alters cofilin conformation and interaction capabilities will enhance our mechanistic understanding. Cryo-electron microscopy of actin filaments decorated with phosphorylated versus non-phosphorylated cofilin could reveal structural insights into how this modification alters filament binding and severing activities at the molecular level.